Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1

OBJECTIVE: To evaluate the efficacy and safety of ixekizumab alone or with concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) versus placebo in patients with active psoriatic arthritis (PsA) as part of a SPIRIT-P1 subgroup analysis (NCT01695239). METHODS: Patients were stratifi...

Descripción completa

Detalles Bibliográficos
Autores principales: Coates, Laura C, Kishimoto, Mitsumasa, Gottlieb, Alice, Shuler, Catherine L, Lin, Chen-Yen, Lee, Chin Hyok, Mease, Philip J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Psoriatic Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5743900/
https://www.ncbi.nlm.nih.gov/pubmed/29299340
http://dx.doi.org/10.1136/rmdopen-2017-000567

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5743900/
https://www.ncbi.nlm.nih.gov/pubmed/29299340
http://dx.doi.org/10.1136/rmdopen-2017-000567

Ejemplares similares